Bardia, A., Kaklamani, V. G., O'Shaughnessy, J., Schmid, P., Beck, J. T., Laurentiis, M. D., Curigliano, G., Rugo, H. S., Barcenas, C. H., Gradishar, W. J., Ignatiadis, M., Cameron, D. A., Tonini, G., Scartoni, S., Crozier, J. A., Wasserman, T., Tolaney, S. M. (2026). ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor–positive (ER+), HER2-negative (HER2−), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps1153